BIOMAT Database Logo BIOMAT Database Logo

GM-CSF therapy in pulmonary alveolar proteinosis. 2002

M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011649 Pulmonary Alveolar Proteinosis A PULMONARY ALVEOLI-filling disease, characterized by dense phospholipoproteinaceous deposits in the alveoli, cough, and DYSPNEA. This disease is often related to, congenital or acquired, impaired processing of PULMONARY SURFACTANTS by alveolar macrophages, a process dependent on GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR. Alveolar Proteinoses, Pulmonary,Alveolar Proteinosis, Pulmonary,Proteinoses, Pulmonary Alveolar,Proteinosis, Pulmonary Alveolar,Pulmonary Alveolar Proteinoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor

Related Publications

M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
[autoimmune pulmonary alveolar proteinosis and GM-CSF inhalation therapy].
August 2011, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
GM-CSF autoantibodies in pulmonary alveolar proteinosis.
May 2007, The New England journal of medicine,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
GM-CSF autoantibodies in pulmonary alveolar proteinosis.
May 2007, The New England journal of medicine,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis.
December 2002, Clinical immunology (Orlando, Fla.),
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
September 2019, The New England journal of medicine,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
January 2020, The New England journal of medicine,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy.
August 2001, Thorax,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice.
April 1999, The American journal of physiology,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
GM-CSF pathway correction in pulmonary alveolar proteinosis.
September 2010, Expert opinion on biological therapy,
M G de Vega, and A Sánchez-Palencia, and A Ramírez, and S Cervera, and J Aneiros
[pulmonary alveolar proteinosis and anti-GM-CSF antibody].
June 2006, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Copied contents to your clipboard!